July 1, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Regulus Therapeutics Inc (NASDAQ:RGLS) shares over potential securities laws violations by Regulus Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Regulus Therapeutics Inc (NASDAQ:RGLS) concerning whether a series of statements by Regulus Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Regulus Therapeutics Inc reported that its annual Total Revenue rose from $7.67 million in 2014 to $20.76 million in 2015 and that its Net Loss declined from $56.68 million in 2014 to $55.75 million in 2015.

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) reached as high as $22.08 per share in 2014 and as high as $20.70 per share in 2015.

On June 27, 2016, Regulus Therapeutics Inc announced during aftermarket hours that it received verbal notice from the U.S. Food and Drug Administration (FDA) that the FDA had placed the Regulus Therapeutics investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold after a second serious adverse event of jaundice was reported.

Shares of Regulus Therapeutics Inc declined on June 28, 2016 to as low as $2.44 per share.